SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Harold Cunningham/Getty Images
Policy
Court Dismisses Whistleblower Lawsuit Against Novartis
A Manhattan court dismissed a whistleblower lawsuit against Novartis, which had alleged the company paid doctors to promote its multiple sclerosis drug Gilenya.
September 14, 2022
 · 
2 min read
 · 
Tristan Manalac
Business
Pretzel Therapeutics Launches with $72M to Advance Mitochondrial Therapies
Pretzel Therapeutics launched Monday with $72.5 million in Series A financing to develop novel, mitochondria-based therapies to treat rare genetic disorders and diseases of aging.
September 12, 2022
 · 
3 min read
 · 
Tristan Manalac
Jeremy Moeller/Getty Images
FDA
BMS Wins Landmark Approval in Plaque Psoriasis, Avoids Black Box Label
BMS announced that the FDA approved Sotyktu for adults with moderate-to-severe plaque psoriasis, marking this indication’s first oral treatment innovation in nearly a decade.
September 12, 2022
 · 
3 min read
 · 
Tristan Manalac
Chesnot/Getty Images
Business
Phase III Data in Hand, Sanofi-Regeneron’s Dupixent Targets Another Approval
Sanofi and Regeneron presented results from the Phase III PRIME trial that showed Dupixent strongly improves itching and skin lesions in adult patients with prurigo nodularis.
September 9, 2022
 · 
2 min read
 · 
Tristan Manalac
Alnylam CEO Yvonne Greenstreet_Alnylam Pharmaceuti
Drug Development
Alnylam’s Patisiran Clears Phase III Hurdle in ATTR With Cardiomyopathy
Alnylam announced results Thursday from the APOLLO-B study of patisiran that showed improved functional capacity in (ATTR) amyloidosis patients with cardiomyopathy.
September 8, 2022
 · 
2 min read
 · 
Tristan Manalac
Pictured: Financing concept/Getty Images
Business
SpringWorks Scores GSK Partnership Expansion, $225M Raise
SpringWorks announced the expansion of its partnership with GlaxoSmithKline to develop nirogacestat in combination with GSK’s Blenrep for relapsed or refractory multiple myeloma.
September 8, 2022
 · 
2 min read
 · 
Tristan Manalac
Andrea Izzotti/Shutterstock
Business
FDA Job Cuts Loom with Partisan Lock in Congress - Updated
Thousands of FDA employees may lose their jobs if Congress doesn’t reappropriate funding currently in place by the end of the month.
September 7, 2022
 · 
3 min read
 · 
Tristan Manalac
Business
Money on the Move: Arcutis Acquires Ducentis and a Hefty Gift to UCSD (Updated)
Arcutis scoops up Ducentis and its lead asset DS-234, UC San Diego receives $150M earmarked for stem cell, regenerative medicine research and Arsenal and ILiAD reel in new funds.
September 7, 2022
 · 
3 min read
 · 
Tristan Manalac
Business
Ionis, AstraZeneca Report Promising Late-Stage Data for ATTR Antisense Candidate
Preliminary findings from the NEURO-TTRansform trial show Ionis’ and AstraZeneca’s eplontersen is potentially a safe and effective treatment for patients with amyloidosis.
September 7, 2022
 · 
3 min read
 · 
Tristan Manalac
Jonathan Weiss/Shutterstock
Drug Development
FDA Okays Imfinzi as First Immunotherapy for Advanced Biliary Tract Cancer
The FDA approved AstraZeneca’s Imfinzi plus with gemcitabine-cisplatin chemotherapy as the first immunotherapy for adult patients with locally advanced or metastatic biliary tract cancer.
September 6, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Michael Vi/Getty Images
Drug Development
Boehringer Bags First FDA Approval for Rare Skin Disease
Boehringer announced that the FDA approved Spevigo for generalized pustular psoriasis flares in adults, the first drug approved for this indication.
September 2, 2022
 · 
2 min read
 · 
Tristan Manalac
Businessperson Walking Out With Exit Sign On Wall
Drug Development
Following Takeda’s Exit, Finch Slashes Headcount, Pauses Trial
Finch announced that it is slashing its headcount by around 37% and suspending its planned Phase I study in autism a week after Takeda withdrew from its multi-year collaboration.
September 2, 2022
 · 
2 min read
 · 
Tristan Manalac
Policy
AstraZeneca Wins Injunction, Blocking Former Exec from Joining GSK
A High Court judge in London granted AstraZeneca an injunction, temporarily blocking a former executive from joining rival pharma GSK.
September 1, 2022
 · 
2 min read
 · 
Tristan Manalac
Chesnot/Getty Images
Drug Development
Sanofi Wins FDA Approval for First ASMD Drug
Sanofi announced FDA approval of Xenpozyme for adult and pediatric patients with the rare genetic disease acid sphingomyelinase deficiency, often referred to as Niemann-Pick disease.
September 1, 2022
 · 
3 min read
 · 
Tristan Manalac
Business
Money on the Move: Mesoblast, Iantrek, Jenavalve and More
Mesoblast fell short of analyst forecasts this week, and money is pouring into glaucoma, medical devices for heart disease and chronic endocrine conditions.
August 31, 2022
 · 
4 min read
 · 
Tristan Manalac
Load More